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Pathogenesis of primary chronic venous disease:
Insights from animal models of venous
hypertension
John J. Bergan, MD, FACS,a Luigi Pascarella, MD,b and Geert W. Schmid-Schönbein, PhD,b LaJolla,
Calif
Background: Reflux of blood through incompetent venous valves is a major cause of the venous hypertension that
underlies clinical manifestations of chronic venous disease, including varicose veins, lipodermatosclerosis, and venous
ulcers.
Objective: To review published literature relating to animal models in which venous hypertension has been produced and
which have yielded information on the mechanisms by which venous hypertension may trigger inflammation and cause
changes in the skin and venous valves.
Methods: Medline searches, with additional papers identified from reference lists in published papers.
Results: At least three types of animal model were identified that have contributed to a better understanding of the trigger
mechanisms and role of inflammatory processes in chronic venous disease. These models involve venous hypertension
induced either by acute venular occlusion, placement of a chronic arteriovenous fistula, or ligation of several large veins.
Model results suggest that elevated venous pressure and altered flow can trigger inflammatory cascades in the vein wall
and venous valves which can cause progressive valvular incompetence and eventual valvular destruction, and which are
also important in the skin changes associated with venous disease. Treatment with agents that reduce oxidative stress by
scavenging free radicals and that inhibit the inflammatory cascade can prevent the progressive deterioration of function
in valves exposed to elevated venous pressure and can prevent the development of reflux blood flow.
Conclusions: Understanding these processes suggests potential therapeutic targets that could be effective in slowing or
preventing progression, and could help promote a more positive and proactive attitude towards treatment of the
underlying disease process, rather than the later manifestations of chronic venous disease. ( J Vasc Surg 2008;47:
183-92.)Venous reflux through incompetent venous valves is a
major cause of the venous hypertension that underlies
many, and possibly all, the clinical manifestations of pri-
mary chronic venous disease (CVD).1,2 Examination of
affected veins from patients with CVD has shown abnor-
malities of valve structure, including thinning, stretching,
and tearing of valve leaflets.3 Microscopic studies have
reported leaflet hypotrophy with collagen abnormalities
and endothelial changes.4,5 The number of valves in a given
venous segment is reduced,6 and degenerated valve stumps
have been identified,7 in veins from patients with CVD.
Valves in veins removed from patients with CVD show
clear signs of inflammation. Monocyte/macrophage infil-
tration of the valve leaflets and venous wall was seen in every
specimen in one surgical series,7 and expression of intercel-
lular adhesion molecule-1 (ICAM-1) was elevated in the
vein wall and valves in another series.8 In patients with
CVD, circulating leukocytes show greater levels of activa-
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production and also contains an (unknown) activating fac-
tor for granulocytes.9 Interestingly, varicose veins from
individuals with a family history of CVD showed elevated
levels of mast cell infiltration, suggesting that inflammation
may be a cause rather than a consequence of venous dis-
ease.10 However, studies in humans can generally give
information only about processes operating in established
disease, whereas the very early stages may be helpful in
understanding pathogenesis and trigger mechanisms. Ani-
mal models have a role to play in this regard. The aim of this
article is to review results that have been obtained using
three different animal models of primary CVD that have
enabled investigation of the mechanisms by which venous
hypertension may trigger inflammation and cause changes
in the skin and venous valves: a mesenteric venule occlusion
model; an arteriovenous fistula model; and a large vein
ligationmodel. Some of the literature was selected based on
ongoing research activities in the authors’ laboratories.
Additional material was found by Medline searching. Al-
though it is not certain that the triggering events in these
models closely reflect those in human CVD, these findings
may be useful in informing future research and therapeutic
decision-making.
MESENTERIC VENULE OCCLUSION MODEL
An acute rodent model in which a mesenteric venule is
exteriorized and reversibly occluded has allowed direct
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venous hypertension, and during reperfusion and return to
normal pressures.11-13
Methods
In anesthetized rats, the mesentery was exposed
through a midline incision, draped on a transparent pedes-
tal on a heated stage, and observed using an intravital
microscope.14 Fluid pressures within venules were mea-
sured with micropipettes using the servo-null technique.15
Single unbranched vessels, at least 350 m long and 35
to 70 m in diameter, were selected and observed for a
20-minute control period. Occlusion of the venule was
performed using a glass micropipette with a smooth
rounded tip, and a region approximately 100 m upstream
of the occlusion was selected for observation. Measure-
ments were taken before occlusion, at 20-minute intervals
during 1 hour of occlusion, and during 1 hour after reper-
fusion. Venules prepared in a similar way but without
occlusion were used as controls.
Investigation of inflammation mechanisms. Levels
of oxidative stress due to hydrogen peroxide (H2O2) were
measured using dichlorofluorescein (DCF) fluores-
cence,16-18 and oxidative stress due to hydroxyl radicals was
assessed using the hydroxyl radical scavenger dimethylthio-
urea (DMTU). Flavonoids are naturally occurring antioxi-
dant substances that can scavenge superoxide anions and
lipid peroxy radicals, and can sequester metal ions.19-21
Their effect was assessed using micronized purified fla-
vonoid fraction (MPFF), which has been shown to reduce
leukocyte adhesion and migration after arterial ischemia/
reperfusion.22-24 MPFF was administered orally for 7 days
before experimentation at doses of 50 and 100 mg/kg
body weight per day, while a control group received vehicle
alone. Cell death in the tissue parenchyma adjacent to the
occluded venule was evaluated by propidium iodide (PI)
staining.25
Results
Venular micropressures upstream of the occlusion in-
creased from 13.4 3.8 mmHg before occlusion to 44
4.7 mm Hg during occlusion, and venular diameters in-
creased by 10% to 20%. There was no change in pressure
downstream of the occlusion.
The number of leucocytes migrating across the venule
wall increased progressively during occlusion, from zero
before occlusion to 5.5 per 100 m length of venule at 1
hour, and increased further during reperfusion to 9.7 per
100 m (P  .05). During reperfusion, the numbers of
rolling and adherent leukocytes increased significantly rel-
ative to preocclusion levels.
Multiple microhemorrhages occurred upstream of the
occlusion. Hemorrhages 20 to 30m in diameter were first
detected after about 23 minutes of occlusion, and ex-
panded and merged to cover an area of mesentery some
200 m in diameter. No hemorrhages were seen at or
downstream of the occlusion. Cell death in the tissue
parenchyma adjacent to the venule was increased signifi-cantly relative to nonoccluded control venules, both during
occlusion and subsequent reperfusion.
It is possible that the observed increase in parenchymal
cell death could have been caused by toxic effects of escaped
red blood cells in the microhemorrhages. However, this
seems unlikely for two reasons. First, there was no colocal-
isation between the PI-positive cells and the microhemor-
rhages. Second, in a separate series of experiments, it was
found that puncturing the venule with micropipette, allow-
ing escape of blood cells and plasma, did not produce an
increase in parenchymal cell death.26
Comparison of upstream and downstream sites. All
the above observations were made at sites upstream of the
occlusion, subjected to both reduced flow (to near zero)
and increased pressure. In order to distinguish between the
effects of these two factors, in a subsequent series of exper-
iments,13 upstream sites were compared with sites down-
stream of the occlusion (which experienced only the reduc-
tion in flow). The number of leukocytes rolling and
adhering during reperfusion, the number migrating into
the interstitial space, and the amount of parenchymal cell
death were all elevated at both sites, and the kinetics of the
changes were similar. However, the degree of elevation was
consistently greater at the upstream site (Fig 1). This sug-
gests that the reduction in flow was sufficient to trigger the
leukocyte cascade at both sites, but the elevated pressure at
the upstream site enhanced the magnitude of the inflam-
matory reactions.
Mechanisms of inflammation. In most experiments,
DCF fluorescence from the endothelium and the mesen-
tery parenchyma increased over time at the same rate in
both control (nonoccluded) and occluded venules. By con-
trast, DMTU and MPFF treatments attenuated the in-
creases in leukocyte rolling, adherence, and migration, and
reduced parenchymal cell death associated with occlusion
(Fig 2, online only, Fig 3). MPFF also significantly in-
creased the delay between occlusion and the first detection
of microhemorrhage, from 23  13 minutes in the vehicle
group to 50  30 minutes and 48  8 minutes in the 50
and 100 mg/kg/day MPFF groups, respectively (P .05
for both doses). MPFF treatment had no significant effect
on DCF fluorescence intensity.
ARTERIO-VENOUS FISTULA MODEL
In order to investigate the effects of venous hyperten-
sion over a longer time scale and in larger veins we have
used a model originally developed by van Bemmelen27 in
which a fistula is created surgically between the femoral
artery and vein in the groin of the rat.28-31
Methods
Under pentobarbital anesthesia, the femoral artery and
vein were clamped, and a fistula of approximately 0.5 mm
internal diameter was created between them, proximal to
the saphenofemoral junction, using monofilament sutures.
Heparin (1000 U/kg body weight) was administered to
prevent blood coagulation, and the incision was closed.
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tained for up to 6 weeks.
To assess the effects of the fistula, rats were anesthe-
tized once more and pressures were measured by catheteri-
sation in the femoral vein 3 cm distal to the fistula, in the
contralateral femoral vein, and in the contralateral femoral
artery. Each femoral vein was then sectioned distal to its
proximal valve, and blood reflux through the valve was
collected over a timed period. The femoral vein distal to the
fistula was then removed for morphometric assessment.
Valve specimens were processed for histology and immu-
nohistochemistry for macrophages, granulocytes and T-
lymphocytes, the matrix metalloproteinases (MMP)-2 and
MMP-9, and the endothelial adhesion molecules P-selectin
and ICAM-1. Terminal deoxynucleotidyl transferase-medi-
ated dUTP nick end labelling (TUNEL) staining for apo-
Fig 1. Comparison of upstream and downstream sites in the
venular occlusion model. A, number of migrating leukocytes per
100 m length of venule. B, proportion of propidium iodide
(PI)-positive cells, a measure of parenchymal cell death, in a tissue
region close to the experimental venule. From Takase et al.13ptotic cells was also performed. In some experiments, ma-trix metalloproteinase (MMP) activity was determined by
gelatin zymography as described by Rosario et al.32
MPFF treatment. The effects of MPFF were investi-
gated in another series of experiments. MPFF (50 and 100
mg/kg/day) or vehicle alone were administered orally for
4 days before fistula placement and continued for 21 days
afterwards, at which time the second surgery and evalua-
tions were performed.
Results
Some investigations and measurements were per-
formed in more than one series of experiments. To avoid
repetition, when results were consistent across experimen-
tal series, a single representative set of results will be pre-
sented.
Reflux rates and valve morphology. Immediately
after fistula creation, the distal femoral and saphenous veins
Fig 2. Effects of the hydroxyl radical scavenger DMTU (2 mM)
at sites upstream of the venular occlusion. A, number of migrating
leukocytes per 100 m length of venule. B, net increase (%) of
propidium iodide (PI)-positive cells, a measure of parenchymal cell
death. From Takase et al.13were visibly distended with pulsatile blood flow through
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some degree of edema of the hind limb ipsilateral to the
fistula. During the second surgery, at the end of the exper-
imental period, pressure in the femoral vein distal to the
fistula was markedly elevated to 94 9 mmHg, compared
with 11 2mmHg in the contralateral femoral vein.Mean
arterial pressure was relatively unchanged in animals with
the fistula (97 8 mmHg) compared with controls (92
4 mm Hg).
No reflux occurred at 1 or 2 days after fistula creation.
By 7 days, the reflux rate was significantly higher than in
controls (P  .05), and the rate was markedly increased at
21 and 42 days (P .01 for both times) (Fig 4, online
Fig 3. Effect of MPFF (50 mg/kg/day and 100 mg/kg/day) at
sites upstream of the venular occlusion. A, number of migrating
leukocytes per 100 m length of venule. B, net increase (%) of
propidium iodide (PI)-positive cells, a measure of parenchymal cell
death. From Takase et al.12only), reflecting progressively greater valvular incompe-tence over time. Macroscopic examination of the terminal
valve in the saphenous vein and the valve just distal to the
fistula in the femoral vein showed significant increases in
valve diameter (to 1.8 mm at day 42 compared with 0.4
mm in controls, (P .01) and reductions in valve height.
The time course of these morphological changes closely
mirrored the development of reflux flow (Fig 4, online
only). Macroscopic disappearance of valves was noted in
the 21- and 42-day groups, and histology confirmed the
complete disappearance of valvular structures at 42 days.
Immunohistochemistry. The numbers of granulo-
cytes, monocytes/macrophages, and T-lymphocytes were
increased in pressurized valves compared with control
valves at 21 days. Expression of the inflammatory markers
P-selectin and ICAM-1 was also greater on the endothe-
lium of saphenous venous valve leaflets.
Matrix metalloproteinases. Results for MMP levels
in vein walls were less consistent across experimental series.
In one series,28 MMP-2 and MMP-9 expression levels,
assayed by immunohistochemistry, were not increased in
the pressurized veins. However, in a later series,31 immu-
nohistochemistry showed a significant increase in MMP-2
Fig 4. Time course of development of reflux and changes in
venous valve morphology after placement of an arteriovenous
fistula (at day 0). A, reflux rate. B, valve diameter. C, valvular
height. Control: unoperated rats; contra: femoral vein con-
tralateral to the fistula (n  15 in each group). From Pascarella
et al.30expression at 21 and 42 days, with no elevation at 1 and 7
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significant elevations at day 1 and again at days 21 and 42.
In a further series of experiments,30 gelatin zymography
showed elevated MMP-2 activity at 21 and 42 days and
elevated MMP-9 activity at 7 days.
MPFF treatment. MPFF treatment significantly at-
tenuated the reduction in valve height in pressurized veins,
although it did not affect the increase in valve diameter.
Importantly, the rate of reflux blood flow at 3 weeks was
markedly reduced byMPFF (P.05), in a dose-dependent
manner (Fig 5).
With MPFF treatment, the numbers of T-lymphocytes
in pressurized valves were reducedmarkedly compared with
vehicle treatment, and were the same as in control valves in
the contralateral, nonpressurized limb (Fig 6, online only).
The numbers of granulocytes and monocytes/macro-
phages in the valve leaflets were all less in MPFF-treated
rats, but the differences did not reach significance. Levels of
P-selectin and ICAM-1 expression in endothelial cells, and
the number of apoptotic, TUNEL positive cells in the vein
wall were all lower with MPFF than in vehicle-treated rats,
but the differences were not significant (Fig 6, online only).
LARGE VEIN LIGATION MODEL
Another rodent model, in which venous hypertension
was produced by ligation of several large veins,33-35 has
been used to investigate the link between venous hyperten-
sion and the skin changes that are important manifestations
of severe clinical CVD.2
Methods
Under pentobarbital anesthesia, the distal vena cava
was ligated and the common femoral veins and common
iliac veins were ligated bilaterally using cotton ties. In acute
experiments, anesthesia was maintained and experimental
Fig 5. Effect of treatment with MPFF 50 mg/kg/day and 100
mg/kg/day, or vehicle alone on reflux flow rates 21 days after
placement of an arteriovenous fistula (n 6 in each group). From
Takase et al.29investigations began directly.33 In the chronic model, theincisions were closed and the rats were maintained for 7 or
14 days before a second anesthesia and investigation.34
Arterial and venous pressure measurements were ob-
tained via cannulation of the right carotid artery and the
right superficial epigastric vein. Tissue distribution of leu-
kocytes was assessed by tissue myeloperoxidase (MPO)
activity.36 One unit of MPO activity is equivalent to ap-
proximately 106 leukocytes in tissues.37
Results
Ligation produced elevation of pressure in the superfi-
cial epigastric vein of the hindlimb in both the acute and
chronic models, from 3.3  1.2 mm Hg in sham-operated
controls to 12.6  3.2 mm Hg in ligated rats at 7 days in
the chronic model.
Tissue MPO activity was significantly increased in the
skin of the hind limb after 135 minutes in acute rats and 7
days in chronic rats compared with skin from the forelimb
or sham-operated hind limb (Fig 7), indicating increased
numbers of leukocytes in skin from the limb exposed to
elevated venous pressure.33,34 Pretreatment with anti-
Fig 6. Effects of fistula placement and MPFF treatment on num-
bers of T-lymphocytes (A), P-selectin expression (B), and apopto-
tic TUNEL-positive cells (C) in saphenous venous valves. Control:
unpressurized, contralateral valves; vehicle, pressurized valves
treated with vehicle alone; MPFF 50 and MPFF 100: pressurized
valves treated withMPFF 50 and 100mg/kg/day. FromTakase et
al.29ICAM-1 monoclonal antibody significantly reduced skin
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 2.46 units (P .001). There was no difference in endo-
thelial expression of ICAM-1 between normotensive and
hypertensive limbs 2 weeks after ligation.35
DISCUSSION
Venular occlusion model
The venular occlusion experiments showed that re-
duced flow can rapidly set in motion an inflammatory
cascade, including hallmarks like leukocyte adhesion to the
endothelium, migration into the interstitium, free radical
production, and parenchymal cell death that begins soon
after occlusion and continues for at least 1 hour after the
occlusion is removed and reperfusion occurs. Normal
blood flow, producing physiological levels of fluid shear
stress transduced by endothelial cells, can inhibit inflamma-
tion by several mechanisms,38 including inhibition of mi-
togen-activated kinase inflammatory pathways,39,40 reduc-
ing expression of adhesion molecules,41 and activating
protective antioxidant mechanisms.42 Shear stress also acts
on leukocytes themselves, causing retraction of pseudo-
pods, down-regulation of CD18 adhesion molecules, and
detachment from the endothelial surface.43-45 Thus, con-
ditions of low or zero flow and shear stress are likely to
promote a shift towards an inflammatory state.
Occlusion of a mesenteric venule also induced a signif-
icant elevation of pressure upstream of the occlusion. In
many microvascular beds, including skeletal muscle, that
have a high level of connectivity with relatively short venu-
lar interconnections, occlusion of any one venule does not
cause a significant increase in pressure upstream of the
occlusion.However, in themesenteric circulation, there are
microvascular domains that are connected to only a single,
relatively long, venous outflow vessel. In such a situation,
occlusion of one outflow vessel causes a significant increase
in capillary pressure and pressure in the portion of the
venule upstream of the occlusion. The addition of elevated
micropressure enhanced the inflammatory reaction caused
Fig 7. Myeloperoxidase (MPO) activity, indicative of tissue leu-
kocyte numbers, in skin samples from the forelimb, sham-operated
hindlimb, and ligated (hypertensive) hindlimb in the rat large vein
ligation model, 7 days after ligation. From Hahn et al.34by flow reduction and produced microhemorrhages. Ele-vated pressure causes stretching of the endothelium, which
can itself cause expression of cytokines and adhesion mol-
ecules,46,47 activation of extracellular signal-related kinases
1 and 2,48 and free radical production.49 Elevated pressure
can also cause the formation of transcellular gaps through
endothelial cells,50 which may be related to the develop-
ment of microhemorrhages. It may be that these processes
reinforce the pro-inflammatory signals generated by the
reduction in flow.
The inflammatory responses seen with venular occlu-
sion are similar to those seen after exposure to inflamma-
tory mediators such as platelet activating factor and N-
formyl-methionyl-leucyl-phenylalanine.51,52 They also
have features in commonwith reactions seen during arterial
occlusion/reperfusion.53-55 The effects of venular occlu-
sion seem to be more severe than arterial occlusion, with
greater parenchymal cell death and microhemorrhage for-
mation. The greater severity may be related to elevated
pressure in capillaries and postcapillary venules produced in
the venular occlusion model.
Results from experiments with DMTU demonstrated
the importance of oxidative stress and free radicals, partic-
ularly the hydroxyl ion, in the inflammatory process. Fla-
vonoids have multiple actions, so MPFF may interfere with
the inflammatory process at several points and so represents
only a nonspecific probe of inflammatory mechanisms.
However, being of low toxicity and active by oral adminis-
tration, MPFF and other flavonoids are of considerable
therapeutic interest.56-58 MPFF is used clinically in some
countries for the treatment of patients with the later man-
ifestations of venous disease and their symptoms, such as
varicose veins, hemorrhoids, and venous ulcers (for review,
see Lyseng-Williamson and Perry59). The present animal
model results suggest thatMPFF is effective in reducing the
initial components of the inflammatory cascade. It is there-
fore possible that MPFF (and potentially other anti-inflam-
matory treatments) could also be of benefit in the early
stages of chronic venous disease and might inhibit inflam-
mation-induced tissue damage and disease progression.
Arterio-venous fistula model
These experiments have demonstrated that formation
of a femoral arteriovenous fistula produces an immediate
increase in venous pressure and dilation of the distal veins.
Detectable reversed flow did not begin immediately, but
rather, the rate of reversed flow increased over the course of
the next 21 days or more. The increasing reflux mirrored
progressive changes in venous valve morphology that were
consistent with those originally reported by van Bemmelen
et al,60 and led in some cases to complete disappearance of
valvular structures at 42 days. Pressurized valves showed
increased numbers of granulocytes, monocytes/macro-
phages, and T-lymphocytes, and elevated levels of inflam-
matory markers. Thickening and fibrosis of the vein wall
were also seen at 21 and 42 days.
Recent studies on the operation of venous valves have
shown that closure normally occurs with no or minimal
reflux, and that blood flowing through the valve separates
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and also a vortical fluidmotion into the sinus pocket behind
the leaflet.61 The vortical flow in the pocket of the valve
prevents stagnation of blood in the valve pocket and en-
sures that all parts of the valvular endothelium are exposed
to significant fluid shear stress. Elevated venous pressure
causes dilation and distortion of the valve, possibly prevent-
ing proper closure of the leaflets, disturbing the flow pat-
tern within the valve, and allowing reflux.
There is considerable evidence that unidirectional, lam-
inar flow (including pulsatile flow) produces shear stress
that is transduced by endothelial cells and causes an anti-
inflammatory response, while zero or low flow is a pro-
inflammatory stimulus.37,60 It is now becoming clear that
disturbed or turbulent flow, and in particular flow whose
direction reverses (often referred to as oscillatory flow with
reciprocating shear stress), also has a pro-inflammatory
action.62-65 Furthermore, elevated pressure itself can acti-
vate pro-inflammatory signalling pathways. Thus, a venous
valve subjected to high pressure, causing structural distor-
tion and disturbed and reversing flow, is likely to display an
inflammatory reaction that may result in tissue damage and
weakening of valvular structures.
The effects of MPFF treatment are important in under-
standing the pathogenetic sequence of events. We propose
that, in the absence ofMPFF, the increased venous pressure
produced by fistula placement distorts the venous valves
exposed to it, altering the flow pattern through the valves
and possibly producing some reflux flow. The altered,
possibly reversed flow and the increased pressure set in
motion an inflammatory reaction that leads to damage of
the valvular tissue, in turn leading to impaired valvular
function and increased reflux flow. In this way, a vicious
cycle of increasing valvular damage and greater reflux is
produced, that may culminate in the complete destruction
of valves. MPFF treatment may inhibit the inflammatory
cascade, reducing valvular tissue damage and preventing
the establishment of this vicious cycle, thereby accounting
for the dose-dependent reduction of reflux flow that was
observed.
It could be argued that placement of an arteriovenous
fistula represents an extreme form of venous hypertension,
in that parts of the venous system are exposed to pressures
90 mm Hg. However, the venous system of the lower
limb in the human can also be exposed to high pressures. A
mean pressure of 95.4  5.5 mm Hg was recorded in the
dorsal foot veins during quiet standing in a group of 20
healthy volunteers aged 22 to 34 years,66 a value consistent
with earlier studies.67 Some vessels in the calf are exposed
to the pressures generated by calf muscle contraction, and
peak intramuscular pressures in the human soleus muscle
have been recorded at 181mmHg during walking and 269
mm Hg during running.68 Proximal venous valves may be
exposed to high pressures caused by intra-abdominal pres-
sure, which has recently been reported to reach 107 mm
Hg during coughing and 171 mm Hg during jumping in
healthy young adults.69 Thus, parts of the human venous
system are exposed to pressures at least as high as thoseproduced by fistula placement in the rat. However, the rat
model is severe in terms of the continuous nature of the
pressure elevation. This may account for the fact that valve
destruction can occur within 6 weeks in the model, but may
progress over many years in human patients.
As well as in primary venous disease, venous valves may
become incompetent secondary to lower limb trauma or
venous thrombosis. Although beyond the main scope of
this article, animal models have been important in showing
that an inflammatory response is also involved in thrombus
formation and the deleterious changes in venous valves and
vein walls that accompany it.70-73 In rodent models of
venous thrombosis, thrombus initiation was associated
with a rapid vein wall inflammatory reaction involving early
neutrophil infiltration,74 and later vein wall remodelling
associated with increased MMP-9 and MMP-2 expres-
sion.75 Inhibition of the pro-inflammatory adhesion mole-
cule P-selectin had no effect on thrombus mass, but re-
duced vein wall injury.73
Large vein ligation model
Skin changes in the lower limb, including hyperpig-
mentation, lipodermatosclerosis and, most seriously, ve-
nous ulcer, are frequent manifestations of long-standing or
severe CVD.2 Studies in humans have shown that blood
returning from feet experiencing venous hypertension due
to calf muscle inactivity is relatively depleted of leuko-
cytes.76,77 Consistent with this phenomenon, the numbers
of macrophages, lymphocytes, andmast cells are elevated in
skin biopsies from patients with CVD.78,79 Results such as
these have led to the “leukocyte trapping hypothesis”,
according to which an inflammatory reaction, involving
leukocyte activation and entrapment in the microcircula-
tion (including capillaries), migration from the microvas-
culature into skin tissue, and accompanied by release of
inflammatory mediators, is important in provoking skin
changes.80,81
Research using the large vein ligation model of venous
hypertension in the rat has shown that a relatively modest
elevation of venous pressure can provoke leukocyte migra-
tion leading to elevated tissue leukocyte levels that are
detectable within approximately 2 hours of ligation and
which persist for at least a week with chronic pressure
elevation.33,34 Leukocyte accumulation was largely pre-
vented by prior injection of an anti-ICAM-1 monoclonal
antibody,35 confirming the key role of ICAM-1 in leuko-
cyte adherence and migration in skin tissue as well as in the
walls and valves of large veins. Interestingly, endothelial
expression of ICAM-1 was not increased after 14 days of
venous hypertension. This may mean that basal levels of
endothelial ICAM-1 expression are sufficient to support
significant leukocyte migration.
Implications for the pathogenesis of primary CVD in
humans
Events that would be predicted, on the basis of animal
model results, to trigger inflammatory reactions are likely
to occur during everyday human activities. Indeed, plasma
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vated and leukocyte “trapping” occurs in normal subjects
in response to the venous hypertension produced by 30
minutes of quiet standing.82 However, in most individuals
such events do not lead to the development of CVD. The
inflammatory cascade is basically a repair mechanism, and
there is a balance between inflammation-induced tissue
injury and the processes of healing and repair. The overall
level of injurymay depend on the intensity and frequency of
triggering events, and a combination of inflammatory stim-
uli are likely more injurious than just a single stimulus. Risk
factors such as prolonged standing, greater body height,
and physical inactivity, together with genetic susceptibility,
may tip the balance in favour of injury and eventually lead
to the clinical manifestations of CVD. In women, the action
of progesterone may be important,83 possibly by reducing
smooth muscle tone and allowing greater venous disten-
sion, compromising the action of venous valves. Once
initiated, venous valve damage will be self-reinforcing, ex-
acerbating venous hypertension and disturbance of venous
flow, and causing further inflammation.
Animal models differ from patients in terms of their
genomes, hemodynamic pressures and flow, and disease
risk factors, so mechanisms identified in animal models
require testing in patients. Nonetheless, animal models
have highlighted the central role of inflammation and elu-
cidated some of the key processes involved. The results
obtained with MPFF and free radical scavengers suggest
that inhibition of the early stages of the inflammatory
cascade offers potential targets for therapeutic intervention.
It may be that existing anti-inflammatory agents warrant
wider use and more detailed study, and there may be
opportunities for the development of novel agents acting in
this area. These findings also suggest that the optimal and
earliest use of those treatment options that are currently
available, including lifestyle changes, aimed at reducing
venous hypertension and inhibiting inflammation, could
minimise valve damage and prevent the development or
worsening of venous reflux. It is to be hoped that future
clinical research will confirm or deny these suggestions
before too long.62
AUTHOR CONTRIBUTIONS
Conception and design: JB
Analysis and interpretation: JB
Data collection: JB
Writing the article: JB
Critical revision of the article: JB
Final approval of the article: JB
Statistical analysis: JB
Obtained funding: JB
Overall responsibility: JB
REFERENCES
1. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation
2005;111:2398-409.2. Bergan JJ, Schmid-Schönbein GW, Coleridge Smith PD, Nicolaides
AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med
2006;355:488-98.
3. Van Cleef JF, Hugentobler JP, Desvaux P, Griton P, Cloarec M.
Endoscopic study of reflux of the saphenous valve. J Mal Vasc 1992:
17(Suppl B):113-6. [Article in French]
4. Budd TW, Meenaghan MA, Wirth J, Taheri SA. Histopathology of
veins and venous valves of patients with venous insufficiency syndrome:
ultrastructure. J Med 1990;21:181-99.
5. Corcos L, De Anna D, Dini M, Macchi C, Ferrari PA, Dini S. Proximal
long saphenous vein valves in primary venous insufficiency. J Mal Vasc
2000;25:27-36.
6. Sales CM, Rosenthal D, Petrillo KA, Jerivs HS, Matsuura J, Clark MD,
et al. The valvular apparatus in venous insufficiency: a problem of
quantity? Ann Vasc Surg 1998;12:153-5.
7. Ono T, Bergan JJ, Schmid-Schönbein GW, Takase S. Monocyte infil-
tration into venous valves. J Vasc Surg 1998;27:158–6.
8. Takase S, Bergan JJ, Schmid-Schönbein GW. Expression of adhesion
molecules and cytokines on saphenous veins in chronic venous insuffi-
ciency. Ann Vasc Surg 2000;14:427-35.
9. Takase S, Schmid-Schönbein GW, Bergan JJ. Leukocyte activation in
patients with venous insufficiency. J Vasc Surg 1999;30:148-56.
10. Kakkos SK, Zolota VG, Peristeropoulou P. Apostolopoulou A, Ger-
oukalos G, Tsolakis IA. Increased mast dell infiltration in familial
varicose veins: pathogenetic implications? Int Angiol 2003;22:43-9.
11. Takase S, DeLano FA, Lerond L, Bergan JJ, Schmid-Schönbein GW.
Inflammation in chronic venous insufficiency: is the problem insur-
mountable? J Vasc Res 1999;36(Suppl 1):3-10.
12. Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. The inflamma-
tory reaction during venous hypertension in the rat. Microcirculation
2000;7:41-52.
13. Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. Enhancement
of reperfusion injury by elevation of microvascular pressures. Am J
Physiol Heart Circ Physiol 2002;282:H1387-94.
14. DeLano FA, Forrest MJ, Schmid-Schönbein GW. Attenuation of oxy-
gen free radical formation and tissue injury during experimental inflam-
mation by P-selectin blockade. Microcirculation 1997;4:349-57.
15. DeLano FA, Schmid-Schönbein GW, Skalak TC, Zweifach BW. Pene-
tration of the systemic blood pressure into the microvasculature of rat
skeletal muscle. Microvasc Res 1991;41:92-110.
16. Cathcart R, Schwiers E, Ames BN. Detection of picomole levels of
hydroperoxides using a fluorescent dichlorofluorescein assay. Anal Bio-
chem 1983;134:111-6.
17. Suematsu M, Schmid-Schönbein GW, Chavez-Chavez RH, Yee TT,
Tamatani T, Miyasaka M, et al. In vivo visualization of oxidative
changes in microvessels during neutrophil activation. Am J Physiol
1993;264:H881-91.
18. Carter WO, Narayanan PK, Robinson JP. Intracellular hydrogen per-
oxide and superoxide anion detection in endothelial cells. J Leukoc Biol
1994;55:253-8.
19. Sorata Y, Takahama U, Kimura M. Protective effect of quercetin and
rutin on photosensitized lysis of human erythrocytes in the presence of
hematoporphyrin. Biochim Biophys Acta 1984;799:313-7.
20. Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide an-
ions. Biochem Pharmacol 1988;37:837-41.
21. Afanas’ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI.
Chelating and free radical scavenging mechanisms of inhibitory action
of rutin and quercetin in lipid peroxidation. Biochem Pharmacol 1989;
38:1763-9.
22. Friesenecker B, Tsai AG, Allegra C, Intaglietta M. Oral administration
of purified micronized flavonoid fraction suppresses leukocyte adhesion
in ischemia-reperfusion injury: in vivo observations in the hamster skin
fold. Int J Microcirc Clin Exp 1994;14:50-5.
23. Bouskela E, Donyo KA. Effects of oral administration of purified
micronized flavonoid fraction on increased microvascular permeability
induced by various agents and on ischemia/reperfusion in the hamster
cheek pouch. Angiology 1997;48391-9.
24. Pickelman S, Nolte D, Leiderer R, Mollmann M, Schutze E, Messmer
K. Effects of the phlebotropic drug Daflon 500 mg on postischemic
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 1 Bergan et al 191reperfusion injury in striated muscle: a histomorphologic study in the
hamster. J Lab Clin Med 1999;134:536-45.
25. Suematsu M, Suzuki H, Ishii H, Kato S, Hamamatsu H, Miura S, et al.
Topographic dissociation between mitochondrial dysfunction and cell
death during low-flow hypoxia in perfused rat liver. Lab Invest 1992;
67:434-42.
26. Wilms H, DeLano FA, Schmid-Schönbein GW. Mechanisms of paren-
chymal cell death in-vivo after microvascular hemorrhage. Microcircu-
lation 2000;7:1-11.
27. van Bemmelen SP. Venous valvular incompetence: and experimental
study in the rat. University of Amsterdam MD Thesis, 1984.
28. Takase S, Pascarella L, Bergan JJ, Schmid-Schönbein GW. Hyperten-
sion-induced venous valve remodeling. J Vasc Surg 2004;39:1329-34.
29. Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schönbein GW.
Venous hypertension, inflammation and valve remodeling. Eur J Vasc
Endovasc Surg 2004;28:484-93.
30. Pascarella L, Penn A, Schmid-Schönbein GW. Venous hypertension
and the inflammatory cascade: major manifestations and trigger mech-
anisms. Angiology 2005;56(Suppl 1):S3-S10.
31. Pascarella L, Schmid-Schönbein GW, Bergan J. An animal model of
venous hypertension: the role of inflammation in venous valve failure. J
Vasc Surg 2005;41:303-11.
32. Rosario HS, Waldo SW, Becker SA, Schmid-Schönbein GW. Pancreatic
trypsin increases matrix metalloproteinase-9 accumulation and activa-
tion during acute intestinal ischemia-reperfusion in the rat. Am J Pathol
2004;164:1707-16.
33. Lalka SG, Unthank JL, Nixon JC. Elevated cutaneous leukocyte con-
centration in a rodent model of acute venous hypertension. J Surg Res
1998;74:59-63.
34. Hahn TL, Unthank JL, Lalka SG. Increased hindlimb leukocyte con-
centration in a chronic rodentmodel of venous hypertension. J Surg Res
1999;81:38-41.
35. Hahn TL, Whitfield R, Salter J, Granger DN, Unthank JL, Lalka SG.
Evaluation of the role of intercellular adhesion molecule 1 in a rodent
model of chronic venous hypertension. J Surg Res 2000;88:150-4.
36. Arndt H, Smith CW, Granger DN. Leukocyte-endothelial cell adhesion
in spontaneously hypertensive and normotensive rats. Hypertension
1993;21:667-73.
37. Granger DN, Zimmerman BJ, Sekizuka E, Grisham MB. Intestinal
microvascular exchange in the rat during luminal perfusion with formyl-
methionyl-leucyl-phenylalanine. Gastroenterology 1988;94:673-81.
38. World CJ, Garin G, Berk B. Vascular shear stress and activation of
inflammatory genes. Curr Atheroscler Rep 2006;8:240-4.
39. Yamawaki H, Lehoux S, Berk BC. Chronic physiological shear stress
inhibits tumor necrosis factor-induced proinflammatory responses in
rabbit aorta perfused ex vivo. Circulation 2003;108:1619-25.
40. Yamawaki H, Pan S, Lee RT, Berk BC. Fluid shear stress inhibits
vascular inflammation by decreasing thioredoxin-interacting protein in
endothelial cells. J Clin Invest 2005; 115:733-8.
41. Chiu J-J, Chen L-J, Lee P-L, Lee C-I, Lo L-W, Usami S, et al. Shear
stress inhibits adhesion molecule expression in vascular endothelial cells
induced by co-culture with smooth muscle cells. Blood 2003;1012:
2667-74.
42. Hojo Y, Saito Y, Tanimoto T, Hoefen RJ, Baines CP, Yamamoto K, et
al. Fluid shear stress attenuates hydrogen peroxide-induced c-JunNH2-
terminal kinase activation via a glutathione reductase-mediated mecha-
nism. Circ Res 2002;91:712-8.
43. Moazzam F, DeLano FA, Zweifach BW, Schmid-Schönbein GW. The
leukocyte response to fluid stress. Proc Natl Acad Sci USA 1997;94:
5338-43.
44. Fukuda S, Schmid-Schönbein GW. Regulation of CD18 expression on
neutrophils in response to fluid shear stress. Proc Natl Acad Sci USA
2003;100:13152-7.
45. Kim MB, Sarelius IH. Role of shear forces and adhesion molecule
distribution on P-selectin-mediated leukocyte rolling in postcapillary
venules. Am J Physiol Heart Circ Physiol 2004;287:H2705-11.
46. Wang DL, Wung BS, Shyy YJ, Chao YJ, Usami S, Chien S. Mechanical
strain induces monocyte chemotactic preotein-1 gene expression in
endothelial cells. Effects of mechanical strain on monocyte adhesion to
endothelial cells. Circ Res 1995;77:294-302.47. Yun JK, Anderson JM, Ziats NP. Cyclic-strain-induced endothelial cell
expression of adhesion molecules and their roles in monocyte-endothe-
lial interaction. J Biomed Mater Res 1999;44:87-97.
48. Cheng JJ, Wung BS, Chao YJ, Wang DL. Sequential activation of
protein kinase C (PKC)-alpha and PKC-epsilon contributes to sus-
tained Raf/ERK1/2 activation in endothelial cells under mechanical
strain. J Biol Chem 2001;276:31368-75.
49. Cheng JJ, Wung BS, Chao YJ, Wang DL. Cyclic strain-induced reactive
oxygen species involved in ICAM-1 gene induction in endothelial cells.
Hypertension 1998;31:125-30.
50. Neal CR, Michel CC. Openings in from microvascular endothelium
induced by high intravascular pressures. J Physiol (Lond) 1996;492:39-
52.
51. Ohashi KL, Tung DK, Wilson J, Zweifach BW, Schmid-Schönbein
GW. Transvascular and interstitial migration of neutrophils in rat mes-
entery. Microcirculation 1996;3:199-210.
52. Tung DK, Bjursten LM, Zweifach BW, Schmid-Schönbein GW. Leu-
kocyte contribution to parenchymal cell death in an experimental model
of inflammation. J Leukoc Biol 1997;62:163-75.
53. Suematsu M, DeLano FA, Poole D, Engler RL, Miyasaka M, Zweifach
BW, et al. Spatial and temporal correlation between leukocyte behavior
and cell injury in post-ischemic rat skeletal muscle microcirculation. Lab
Invest 1994;70:684-95.
54. Harris AG, Costa JJ, DeLano FA, Zweifach BW, Schmid-Schönbein
GW. Mechanisms of cell injury in rat mesentery and cremaster muscle.
Am J Physiol 1998;274:H1009-15.
55. Carden DL, Granger DN. Pathophysiology of ischemia-reperfusion
injury. J Pathol 2000;190:255-66.
56. Frick RW. Three treatment for chronic venous insufficiency: escin,
hydroxyethylrutoside, and Daflon. Angiology 2000;51:197-205.
57. Bergan JJ, Schmid-Schönbein GW, Takase S. Therapeutic approach to
chronic venous insufficiency and its complications: place of Daflon 500
mg. Angiology 2001;52(Suppl 1):S43-7.
58. Di Carlo A, Passi S, Ippolito F, Candiani C. Free radical scavenging
activity of rutosides. Minerva Cardioangiol 2002;50:701-7.
59. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid frac-
tion: a review of its use in chronic venous insufficiency, venous ulcers
and haemorrhoids. Drugs 2003;63:71-100.
60. van Bemmelen SP, Hoynck van Papendrecht AA, Hodde KC, Klopper
PJ. A study of valve incompetence that developed in an experimental
model of venous hypertension. Arch Surg 1986;121:1048-52.
61. Lurie F, Kistner RL, Eklof B, Kessler D. Mechanism of venous valve
closure and role of the valve in circulation: a new concept. J Vasc Surg
2003;38:955-61.
62. Li YS, Haga JH, Chien S.Molecular basis of the effects of shear stress on
vascular endothelial cells. J Biomech 2005;38:1949-71.
63. Hwang J, Saha A, Boo YC, Sorescu GP, McNally JS, Holland SM, et al.
Oscillatory shear stress stimulates endothelial production of O2- from
p47phox-dependent NAD(P)H oxidases, leading to monocyte adhe-
sion. J Biol Chem 2003;278:47291-8.
64. Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, Hwang J, et al. Bone
morphogenic protein 4 produced in endothelial cells by oscillatory
shear stress stimulates an inflammatory response. J Biol Chem 2003;
278:31128-35.
65. Hosoya T, Maruyama A, KangMI, Kawatani Y, Shibata T, Uchida K, et
al. Differential responses of the Nrf2-Keap1 system to laminar and
oscillatory shear stresses in endothelial cells. J Biol Chem 2005;280:
27244-50.
66. Kügler C, Strunk M, Rudofsky G. Venous pressure dynamics of the
healthy human leg. J Vasc Res 2001;38:20-29.
67. Stick C, Jaeger H, Witzleb E. Measurements of volume changes and
venous pressure in the human lower leg during walking and running.
J Appl Physiol 1992;72:2063-8.
68. Ballard RE, Watenpaugh DE, Breit GA, Murthy G, Holley DC, Har-
gens AR. Leg intramuscular pressures during locomotion in humans.
J Appl Physiol 1998;84:1976-81.
69. Cobb WS, Burns JM, Kercher KW, Matthews BD, Norton HJ, Heni-
ford BT. Normal intra-abdominal pressure in healthy adults. J Surg Res
2005;129:231-5.
JOURNAL OF VASCULAR SURGERY
January 2008192 Bergan et al70. Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK,
Burdick MD, et al. Venous thrombosis-associated inflammation and
attenuation with neutralizing antibodies to cytokines and adhesion
molecules. Arterioscler Thromb Vasc Biol 1995; 15:258-68.
71. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P,
Schaub RG, et al. P-selectin and leukocyte microparticles are associated
with venous thrombogenesis. J Vasc Surg 2003;38:1075-89.
72. Myers DD,Wakefield TW. Inflammation-dependent thrombosis. Front
Biosci 2005;10:2750-7.
73. Myers DD Jr, Henke PK, Bedard PW, Wrobleski SK, Kaila N, Shaw G,
et al. Treatment with an oral small molecule inhibitor of P-selectin
(PSI-6797) decreases vein wall injury in a rat stenosis model of venous
thrombosis. J Vasc Surg 2006;44:625-32.
74. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Brown SL, Wrobleski
SK, et al. Neutrophils are the initial cell type identified in deep venous
thrombosis induced vein wall inflammation. ASAIO J 1996;42:M677-82.
75. Deatrick KB, Eliason JL, Lynch EM, Moore AJ, Dewyer NA, Varma
MR, et al. Vein wall remodeling after deep vein thrombosis involves
matrix metalloproteinases and late fibrosis in a mouse model. J Vasc
Surg 2005;42:140-8.
76. Moyses C, Cederholm-Williams SA, Michel CC. Hemoconcentration
and accumulation of white cells in the feet during venous stasis. Int J
Microcirc Clin Exp 1987;5:311-20.
77. Thomas PR, Nash GB, Dormandy JA. White cell accumulation in
dependent legs of patients with venous hypertension: a possible mech-78. Wilkinson LS, Bunker C, Edwards JC, Scurr JH. Leukocytes: their role
in the etiopathogenesis of skin damage in venous disease. J Vasc Surg
1993;17:669-75.
79. Pappas PJ, DeFouw DO, Venezio LM, Gorti R, Padberg FT Jr, Silva
MB Jr, et al. Morphometric assessment of the dermal microcirculation
in patients with chronic venous insufficiency. J Vasc Surg 1997;26:784-
95.
80. Cheatle TR, Sarin S, Coleridge Smith PD, Scurr JH. The pathogenesis
of skin damage in venous disease: a review. Eur J Vasc Surg 1991;5:
115-23.
81. Coleridge Smith PD. The microcirculation in venous hypertension.
Vasc Med 1997;2:203-13.
82. Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH,
Coleridge Smith PD. Endothelial activation in patients with chronic
venous disease. Eur J Vasc Endovasc Surg 1998;15:342-9.
83. Perrot-Applanat M, Cohen-Solal K, Milgrom E, Finet M. Progesterone
receptor expression in human saphenous veins. Circulation 1995;92:
2975-83.
Submitted Jun 15, 2007; accepted Sep 3, 2007.
Additional material for this article may be found online
anism for trophic changes in the skin. BMJ 1988;296:1693-5. at www.jvascsurg.org.
